Vanda Pharmaceuticals | VNDA - Current Liabilities


Vanda Pharmaceuticals reported $145.16M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Akebia Therapeutics USD 162.94M 29.56M Dec/2025
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 347.42M 151.94M Dec/2025
AstraZeneca USD 32.57B 1.95B Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
J&J USD 57.72B 3.59B Mar/2026
Lexicon Pharmaceuticals USD 20.87M 853K Dec/2025
Ligand Pharmaceuticals USD 37.45M 6.91M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 2.4B 408M Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Takeda JPY 2.61T 470.53B Dec/2025
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026
Ultragenyx Pharmaceutical USD 384M 43.98M Dec/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Veracyte USD 59.94M 12.22M Dec/2025